David Sermer

778 total citations
22 papers, 387 citations indexed

About

David Sermer is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, David Sermer has authored 22 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 6 papers in Molecular Biology. Recurrent topics in David Sermer's work include CAR-T cell therapy research (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). David Sermer is often cited by papers focused on CAR-T cell therapy research (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). David Sermer collaborates with scholars based in United States, United Kingdom and South Korea. David Sermer's co-authors include Renier J. Brentjens, Ari Melnick, Anas Younes, Laura Pasqualucci, Hans‐Guido Wendel, Kenneth I. Kaitin, Kenneth Getz, Robert E. Martell, Andrew R. Branagan and Jon Arnason and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Clinical Oncology.

In The Last Decade

David Sermer

21 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Sermer United States	10	219	112	106	93	54	22	387
Qingsong Yin China	8	156 0.7×	79 0.7×	97 0.9×	97 1.0×	108 2.0×	66	320
Lori A. Leslie United States	11	252 1.2×	61 0.5×	168 1.6×	84 0.9×	125 2.3×	73	412
Sandra P. Susanibar-Adaniya United States	7	172 0.8×	121 1.1×	137 1.3×	52 0.6×	57 1.1×	28	332
Alessandro Previtali United States	7	257 1.2×	84 0.8×	111 1.0×	76 0.8×	43 0.8×	18	374
Nicole Adrian Germany	8	323 1.5×	85 0.8×	192 1.8×	131 1.4×	66 1.2×	10	428
Eri Matsuki Japan	11	249 1.1×	61 0.5×	134 1.3×	132 1.4×	127 2.4×	41	492
Andrea N. Marcogliese United States	9	187 0.9×	158 1.4×	66 0.6×	113 1.2×	32 0.6×	23	381
Mingzhi Zhang China	9	334 1.5×	110 1.0×	47 0.4×	165 1.8×	22 0.4×	19	432
Alina Danu France	10	246 1.1×	47 0.4×	169 1.6×	104 1.1×	34 0.6×	38	377
Carlo Alberto Giorgi Italy	12	280 1.3×	51 0.5×	58 0.5×	76 0.8×	87 1.6×	35	513

Countries citing papers authored by David Sermer

Since Specialization

Citations

This map shows the geographic impact of David Sermer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sermer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sermer more than expected).

Fields of papers citing papers by David Sermer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sermer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sermer. The network helps show where David Sermer may publish in the future.

Co-authorship network of co-authors of David Sermer

This figure shows the co-authorship network connecting the top 25 collaborators of David Sermer. A scholar is included among the top collaborators of David Sermer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sermer. David Sermer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gaballa, Sameh, Jing‐Zhou Hou, Sumana Devata, et al.. (2024). Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients. Blood. 144(Supplement 1). 868–868. 4 indexed citations

Hou, Jing‐Zhou, Ranjit Nair, Ryan Jacobs, et al.. (2024). Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma. Blood. 144(Supplement 1). 341–341. 9 indexed citations

Kim, Eunice, et al.. (2024). Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. The Oncologist. 30(2). 3 indexed citations

Zhu, Xu, César Pichardo‐Almarza, Kevin Smart, et al.. (2024). Exposure-Response Analysis and Quantitative Systems Pharmacology Modeling for Optimal RP2D Selection of AZD0486 in Follicular Lymphoma Patients. Blood. 144(Supplement 1). 2794–2794. 2 indexed citations

Gaballa, Sameh, Ranjit Nair, Ryan Jacobs, et al.. (2023). Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial. Blood. 142(Supplement 1). 1662–1662. 14 indexed citations

Sermer, David, Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, & Jorge J. Castillo. (2022). SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma & Leukemia. 22(8). 547–556. 8 indexed citations

Sarosiek, Shayna, David Sermer, Andrew R. Branagan, Steven P. Treon, & Jorge J. Castillo. (2022). Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Review of Anticancer Therapy. 22(5). 471–478. 3 indexed citations

Sermer, David, et al.. (2022). Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation. Blood Reviews. 57. 101002–101002. 17 indexed citations

Castillo, Jorge J., Shayna Sarosiek, Andrew R. Branagan, et al.. (2022). Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia. Blood. 140(Supplement 1). 564–565. 10 indexed citations

10.

Bindal, Poorva, Caitlin A. Trottier, Laura E. Dodge, et al.. (2022). G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy. Blood. 140(Supplement 1). 5238–5240. 3 indexed citations

11.

Sermer, David, Santosha A. Vardhana, Alison J. Moskowitz, et al.. (2020). Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).. Journal of Clinical Oncology. 38(15_suppl). e20018–e20018. 4 indexed citations

12.

Sermer, David, Laura Pasqualucci, Hans‐Guido Wendel, Ari Melnick, & Anas Younes. (2019). Emerging epigenetic-modulating therapies in lymphoma. Nature Reviews Clinical Oncology. 16(8). 494–507. 94 indexed citations

13.

Sermer, David & Renier J. Brentjens. (2019). CAR T‐cell therapy: Full speed ahead. Hematological Oncology. 37(S1). 95–100. 138 indexed citations

14.

Bobillo, Sabela, Erel Joffe, Venkatraman Seshan, et al.. (2019). Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. Blood. 134(Supplement_1). 1619–1619. 1 indexed citations

15.

Sermer, David, Santosha A. Vardhana, Connie Lee Batlevi, et al.. (2019). SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL). Hematological Oncology. 37(S2). 331–332. 1 indexed citations

16.

Sermer, David, Sabela Bobillo, Venkatraman Seshan, Ahmet Doǧan, & Anas Younes. (2019). CLINICAL SIGNIFICANCE AND OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) HARBORING EXTRA COPIES [EC] AND/OR TRANSLOCATIONS [TL] OF MYC, BCL2, AND BCL6. Hematological Oncology. 37(S2). 349–350.

17.

Ramalingam, Sundhar, David Sermer, Rajan T. Gupta, et al.. (2016). Changes in skeletal muscle cross sectional area (CSA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ).. Journal of Clinical Oncology. 34(15_suppl). e16601–e16601. 2 indexed citations

18.

Sermer, David, et al.. (2014). Herpes Simplex Encephalitis as a Complication of Whole-Brain Radiotherapy: A Case Report and Review of the Literature. Case Reports in Oncology. 7(3). 774–779. 12 indexed citations

19.

Martell, Robert E., David Sermer, Kenneth Getz, & Kenneth I. Kaitin. (2012). Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration. The Oncologist. 18(1). 104–111. 30 indexed citations

20.

Sermer, David, Nada Quercia, Karen Chong, & David Chitayat. (2007). Acrofacial dysostosis syndrome type Rodriguez: Prenatal diagnosis and autopsy findings. American Journal of Medical Genetics Part A. 143A(24). 3286–3289. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact